J. Goldman & CO LP Athenex, Inc. Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$9.6 - $17.75 $940,281 - $1.74 Million	-97,946 Reduced 24.61%	300,000 $4.58 Million
Q3 2019 Nov 14, 2019	BUY	$12.16 - $21.0 $2.64 Million - $4.57 Million	217,494 Added 120.53%	397,946 $4.84 Million
Q2 2019 Aug 14, 2019	SELL	$9.44 - $19.8 $5.44 Million - $11.4 Million	-576,155 Reduced 76.15%	180,452 $3.57 Million
Q1 2019 May 14, 2019	BUY	$11.11 - $13.49 $512,082 - $621,781	46,092 Added 6.49%	756,607 $9.27 Million
Q4 2018 Feb 14, 2019	BUY	$10.24 - $15.49 $2.95 Million - $4.47 Million	288,515 Added 68.37%	710,515 $9.02 Million
Q3 2018 Nov 14, 2018	BUY	$15.53 - $19.97 $2.13 Million - $2.74 Million	137,129 Added 48.14%	422,000 $6.56 Million
Q2 2018 Aug 14, 2018	SELL	$15.88 - $19.5 $6.8 Million - $8.35 Million	-428,357 Reduced 60.06%	284,871 $5.32 Million
Q1 2018 May 15, 2018	BUY	$13.53 - $17.47 $9.65 Million - $12.5 Million	713,228 New	713,228 $12.1 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.